Role of Inflammatory Cytokines in the Conversion of Mild Cognitive Impairment to Dementia: A Prospective Study.

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY Current Alzheimer research Pub Date : 2022-01-01 DOI:10.2174/1567205019666220127102640

Raúl Romero-Sevilla, Fidel López-Espuela, José Manuel Fuentes, Beatriz Duque de San Juan, Juan Carlos Portilla-Cuenca, Carmen Cámara Hijon, Ignacio Casado-Naranjo

{"title":"Role of Inflammatory Cytokines in the Conversion of Mild Cognitive Impairment to Dementia: A Prospective Study.","authors":"Raúl Romero-Sevilla, Fidel López-Espuela, José Manuel Fuentes, Beatriz Duque de San Juan, Juan Carlos Portilla-Cuenca, Carmen Cámara Hijon, Ignacio Casado-Naranjo","doi":"10.2174/1567205019666220127102640","DOIUrl":null,"url":null,"abstract":"Background: The effect that cytokines can exert on the progression from mild cognitive impairment (MCI) to ongoing dementia is a matter of debate and the results obtained so far are controversial.Objective: The aim of the study is to analyze the influence of markers of subclinical inflammation on the progression of MCI to dementia.Methods: A prospective study involving a cohort of patients ≥ 65 years of age diagnosed with MCI and followed for 3 years was conducted. 105 patients were enrolled, and serum concentrations of several subclinical inflammatory markers were determined.Results: After 3.09 (2 - 3.79) years of follow-up, 47 (44.76%) patients progressed to dementia. Alpha 1-antichymotrypsin (ACT) was found to be significantly higher in patients who progressed to dementia (486.45 ± 169.18 vs. 400.91 ± 163.03; p = 0.012), and observed to significantly increase the risk of developing dementia in patients with mild cognitive impairment (1.004, 1.001-1.007; p = 0.007). IL-10 levels were significantly higher in those who remained stable (6.69 ± 18.1 vs. 32.54 ± 89.6; p = 0.04). Regarding the type of dementia to which our patients progressed, we found that patients who developed mixed dementia had higher IL-4 levels than those who converted to AD (31.54 ± 63.6 vs. 4.43 ± 12.9; p = 0.03). No significant differences were observed between the groups with regard to the ESR and LPa, CRP, IL-1 and TNF-α levels.Conclusion: ACT levels have a significant predictive value in the conversion of MCI to dementia. IL-10 levels could be a protective factor. It is necessary to conduct studies with serial determinations of these and other inflammatory markers in order to determine their effect on the progression of MCI to dementia.","PeriodicalId":10810,"journal":{"name":"Current Alzheimer research","volume":"19 1","pages":"68-75"},"PeriodicalIF":1.8000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Alzheimer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1567205019666220127102640","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Background: The effect that cytokines can exert on the progression from mild cognitive impairment (MCI) to ongoing dementia is a matter of debate and the results obtained so far are controversial.

Objective: The aim of the study is to analyze the influence of markers of subclinical inflammation on the progression of MCI to dementia.

Methods: A prospective study involving a cohort of patients ≥ 65 years of age diagnosed with MCI and followed for 3 years was conducted. 105 patients were enrolled, and serum concentrations of several subclinical inflammatory markers were determined.

Results: After 3.09 (2 - 3.79) years of follow-up, 47 (44.76%) patients progressed to dementia. Alpha 1-antichymotrypsin (ACT) was found to be significantly higher in patients who progressed to dementia (486.45 ± 169.18 vs. 400.91 ± 163.03; p = 0.012), and observed to significantly increase the risk of developing dementia in patients with mild cognitive impairment (1.004, 1.001-1.007; p = 0.007). IL-10 levels were significantly higher in those who remained stable (6.69 ± 18.1 vs. 32.54 ± 89.6; p = 0.04). Regarding the type of dementia to which our patients progressed, we found that patients who developed mixed dementia had higher IL-4 levels than those who converted to AD (31.54 ± 63.6 vs. 4.43 ± 12.9; p = 0.03). No significant differences were observed between the groups with regard to the ESR and LPa, CRP, IL-1 and TNF-α levels.

Conclusion: ACT levels have a significant predictive value in the conversion of MCI to dementia. IL-10 levels could be a protective factor. It is necessary to conduct studies with serial determinations of these and other inflammatory markers in order to determine their effect on the progression of MCI to dementia.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

炎症细胞因子在轻度认知障碍向痴呆转化中的作用:一项前瞻性研究。

背景:细胞因子对轻度认知障碍(MCI)发展为持续性痴呆的影响是一个有争议的问题，迄今为止获得的结果是有争议的。目的:分析亚临床炎症标志物对轻度认知损伤向痴呆发展的影响。方法:前瞻性研究纳入≥65岁诊断为轻度认知损伤的患者，随访3年。105名患者被纳入研究，并测定了几种亚临床炎症标志物的血清浓度。结果:随访3.09(2 ~ 3.79)年，47例(44.76%)患者进展为痴呆。α 1-抗凝乳胰蛋白酶(ACT)在进展为痴呆的患者中显著升高(486.45±169.18∶400.91±163.03;P = 0.012)，并观察到轻度认知障碍患者发生痴呆的风险显著增加(1.004,1.001-1.007;P = 0.007)。IL-10水平在病情稳定的患者中显著升高(6.69±18.1∶32.54±89.6;P = 0.04)。关于患者进展为痴呆的类型，我们发现混合性痴呆患者的IL-4水平高于转化为AD的患者(31.54±63.6∶4.43±12.9;P = 0.03)。两组间ESR、LPa、CRP、IL-1、TNF-α水平无显著差异。结论:ACT水平对MCI向痴呆的转化具有重要的预测价值。IL-10水平可能是一个保护因素。有必要对这些和其他炎症标志物进行一系列测定，以确定它们对MCI向痴呆进展的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Alzheimer research 医学-神经科学

CiteScore

4.00

自引率

4.80%

发文量

审稿时长

4-8 weeks

期刊介绍： Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies and letter articles on all areas of Alzheimer’s disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer’s disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer’s disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer''s disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer’s disease. Current Alzheimer Research provides a comprehensive ''bird''s-eye view'' of the current state of Alzheimer''s research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.